ClinicalTrials.gg
CompletedNCT05624723Updated Feb 13, 2024

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

A Phase 1 interventional study of INCB054707 in Renal Insufficiency and Kidney Diseases, sponsored by Incyte Corporation. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 82 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
169th of 468
43 · median 32
Started
2023
with 20 others
Phase 1
232 of 553
14 open now
Registered
476th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 169th largest by enrollment of the 468 interventional ones that give a count, is one of 21 that started in 2023, is one of 232 in phase 1, and was the 476th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 82 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.

03

Conditions studied

  • Renal Insufficiency
  • Kidney Diseases

Keywords

  • renal impairment
  • hemodialysis
  • Kidney failure
  • end-stage renal disease
04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Classification at screening by renal function based on as calculated by the MDRD formula and requirement for HD (Group 5).
  • Participants eligible for Group 5 with ESRD have received HD for at least 3 months prior to screening.
  • Participants eligible for Group 1 should be in good health as determined by no deviations from normal for medical history, physical examination, vital signs, 12-lead ECGs, or clinical laboratory determinations at screening or Day -1.
  • Participants eligible for Groups 2 through 5 may have medical findings consistent with their degree of renal dysfunction, as determined by medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory determinations at screening and Day -1 (Groups 2 through 4) or Period 1 Day -1 (Group 5).
  • within the range of 18.0 to 40.0 kg/m2 (inclusive) at screening.
  • Willingness to avoid pregnancy or fathering children

Exclusion criteria

Exclusion Criteria:

  • History of uncontrolled or unstable cardiovascular, respiratory, hepatic, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening or evidence of rapidly deteriorating renal function.
  • Current, functioning organ transplant or a cheduled organ transplant within 6 weeks after check-in.
  • History of within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
  • History of GI disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug.
  • Eligible for Group 1 and have a history of renal disease or renal injury as indicated by an abnormal, clinically significant renal function profile at screening or Day -1.
  • Eligible for Groups 2 through 5 and have had a change in disease status within 30 days of screening, as documented by the participant's medical history and deemed clinically significant by the investigator.
  • History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including any of the following:

    1. Recent myocardial infarction (within 6 months of check-in)
    2. Class III or IV congestive heart failure
    3. Unstable angina (within 6 months of check-in)
    4. Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second- or third-degree atrioventricular block without a pacemaker)
    5. Uncontrolled hypertension
  • Any major surgery within 4 weeks of screening.
  • Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only).
  • Blood transfusion within 4 weeks of Day -1 (for Groups 1 through 4) or Period 1 Day -1 (Group 5).
  • Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
  • Positive test and symptomatic for , , or . Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator.
  • Eligible for Group 1 and have a history of using tobacco- or nicotine-containing products within 6 months of screening.
  • Eligible for Groups 2 through 5 and smoke > 10 cigarettes per day or equivalent use of other tobacco- or nicotine-containing products and are unwilling to refrain from tobacco or nicotine use on dosing days and abide by CRU restrictions.
  • History of alcohol dependency within 3 months of screening.
  • Positive breath test for ethanol or positive urine or saliva screen for drugs of abuse (confirmed by repeat test) at screening or check-in that are not otherwise explained by permitted concomitant medications.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with another medication or current enrollment in another investigational drug study.
  • Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before the first dose of study drug with moderate and potent inducers or inhibitors of (refer to the Drug Interaction Database Program [University of Washington School of Pharmacy 2002] for prohibited drugs).
  • Consumption of Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 72 hours before the first dose of study drug.
  • Eligible for Group 1 and have used prescription drugs within 14 days of study drug administration or nonprescription medications/products (including vitamins, minerals, and hytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug administration. However, occasional use of acetaminophen and ibuprofen is permitted (see Section 6.6.1).
  • Eligible for Groups 2 through 5 and have used prescription drugs within 14 days of study drug administration, with the exception of established therapy for renal disease and the treatment of associated disorders that have been stable for at least 7 days prior to study drug administration, as approved by the investigator and in consultation with the sponsor's medical monitor.
  • Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, currently receiving systemic antibiotics, or having a current clinically significant viral infection at screening or check-in.
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
  • Inability to undergo venipuncture or tolerate venous access.
  • Eligible for Group 5 and not expected to continue HD treatment for the duration of the study.
  • Women who are pregnant or breastfeeding.
  • Use of hormonal
  • > 450 milliseconds for Groups 1 through 3 and QTcF > 470 milliseconds for Group 4.
  • Eligible for Group 1 and have abnormal LFT values, defined as , alanine aminotransferase, and serum (total and direct) , as well as amylase and lipase above the at screening.
  • Eligible for Groups 2 through 4 and have values outside the normal ranges for LFTs; however, values may be acceptable if they are consistent with the participant's renal condition (if stable for 1 month prior to screening) and if the investigator (or designee) and the sponsor feel that the results are not clinically significant (based on age and renal impairment status).
  • Receipt of live (including attenuated) vaccines within 3 months of check-in or anticipation of need for such a vaccine during the study (Note: Nonlive or inactivated vaccines are allowed up to 2 weeks prior to the first dose of study drug).
  • Known or severe reaction to INCB054707 or of INCB054707 (refer to the IB).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Group 1: Normal Renal Function

    Participants with normal levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.

    Drug: INCB054707

  • Experimental
    Group 2: Mild Renal Impairment

    Participants with mild levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.

    Drug: INCB054707

  • Experimental
    Group 3: Moderate Renal Impairment

    Participants with moderate levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.

    Drug: INCB054707

  • Experimental
    Group 4: Severe Renal Impairment

    Participants with severe levels of renal function will receive a single oral dose of INCB054707 75 mg on Day 1.

    Drug: INCB054707

  • Experimental
    Group 5: Kidney Failure

    Group 5 participants with ESRD maintained on HD will receive a single dose of INCB054707 across 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB054707.

    Drug: INCB054707

Interventions

  • INCB054707 75 mg will be administered orally

    Also known as: Povorcitinib

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics Parameter: Cmax of INCB054707

    Defined as maximum observed plasma concentration of INCB054707

    Time frame: Days 1-4

  2. Pharmacokinetics Parameter: AUC0-t of INCB054707

    Area Under the concentration- time curve up to the last measurable concentration of INCB054707

    Time frame: Days 1-4

  3. Pharmacokinetics Parameter: AUC0-∞ of INCB54707

    Defined as under the concentration-time curve up to the last measurable concentration of INCB054707

    Time frame: Days 1-4

Secondary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAE'S)

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

    Time frame: Up to 21 days

  2. Pharmacokinetics Parameter: tmax of INCB054707

    Defined as time to reach maximum plasma concentration of INCB054707; during dialysis for Group 5 Period 1.

    Time frame: Days 1-4

  3. Pharmacokinetics Parameter: t½ of INCB054707

    Defined as apparent terminal-phase disposition half-life of INCB054707; during dialysis for Group 5 Period 1.

    Time frame: Days 1-4

  4. Pharmacokinetics Parameter: CL/F of INCB054707

    Defined as oral dose clearance of INCB054707; during dialysis for Group 5 Period 1.

    Time frame: Days 1-4

  5. Pharmacokinetics Parameter: Vz/F of INCB054707

    Defined as apparent oral dose volume of distribution; during dialysis for Group 5 Period 1.

    Time frame: Days 1-4

  6. Pharmacokinetics Parameter: AUC3-7 of INCB054707

    Defined as area under the concentration-time curve from 1 to 5 of INCB054707; during dialysis for Group 5 Period 1.

    Time frame: Days 1-4

07

Study locations

2 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Apex Gmbh
    Munich, D-81241, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Feb 2024, 12 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 12 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2022
First posted
Nov 22, 2022
StartActual
Jan 12, 2023
Primary completionActual
Feb 7, 2024
CompletionActual
Feb 7, 2024
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05624723
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Jan 12, 2023
Primary completion
Feb 7, 2024
Completion
Feb 7, 2024
Last update
Feb 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion